BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sulkowski M, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. Adv Ther 2021;38:423-40. [PMID: 33145648 DOI: 10.1007/s12325-020-01535-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 O'Brien M, Daws R, Amin P, Lee K. Utilizing Telemedicine and Modified Fibrosis Staging Protocols to Maintain Treatment Initiation and Adherence Among Hepatitis C Patients During the COVID-19 Pandemic. J Prim Care Community Health 2022;13:21501319221108000. [PMID: 35748428 DOI: 10.1177/21501319221108000] [Reference Citation Analysis]
2 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
3 Mirzazadeh A, Facente SN, Burk K, Kahn JG, Morris MD; End Hep C SF. Hepatitis C mortality trends in San Francisco: can we reach elimination targets? Ann Epidemiol 2021;65:59-64. [PMID: 34700016 DOI: 10.1016/j.annepidem.2021.10.004] [Reference Citation Analysis]
4 Auty SG, Shafer PR, Griffith KN. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications. JAMA Health Forum 2021;2:e212291. [DOI: 10.1001/jamahealthforum.2021.2291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Narayanamurthy V, Jeroish ZE, Bhuvaneshwari KS, Samsuri F. Hepatitis C virus (HCV) diagnosis via microfluidics. Anal Methods 2021;13:740-63. [PMID: 33511975 DOI: 10.1039/d0ay02045a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Martin MT, Waring N, Forrest J, Nazari JL, Abdelaziz AI, Lee TA. Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access. Public Health Rep. [DOI: 10.1177/00333549221099323] [Reference Citation Analysis]
7 Saha R, Miller AP, Parriott A, Horvath H, Kahn JG, Malekinejad M. Viral blood-borne infections testing and linkage to care cascade among persons who experience homelessness in the United States: a systematic review and meta-analysis. BMC Public Health 2022;22:1421. [PMID: 35883158 DOI: 10.1186/s12889-022-13786-6] [Reference Citation Analysis]
8 Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study. Clin Infect Dis 2021:ciab779. [PMID: 34499124 DOI: 10.1093/cid/ciab779] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chan K, Mangla N. Prevalence and risk factors of hepatitis C virus infection in the rural northeastern United States. Ann Hepatol 2021;:100576. [PMID: 34752949 DOI: 10.1016/j.aohep.2021.100576] [Reference Citation Analysis]